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The risks and beneﬁts of adding ﬂudarabine to a 2-Gy total body irradiation (TBI) nonmyeloablative regimen
are unknown. For this reason, we conducted a prospective randomized trial comparing 2-Gy TBI alone, or in
combination with 90 mg/m2 ﬂudarabine (FLU/TBI), before transplantation of peripheral blood stem cells from
HLA-matched related donors. Eighty-ﬁve patients with hematological malignancies were randomized to be
conditioned with TBI alone (n ¼ 44) or FLU/TBI (n ¼ 41). All patients had initial engraftment. Two graft
rejections were observed, both in the TBI group. Infection rates, nonrelapse mortality, and graft-versus-host
disease (GVHD) were similar between groups. Three-year overall survival was lower in the TBI group (54%
versus 65%; hazard ratio [HR], .57; P ¼ .09), with higher incidences of relapse/progression (55% versus 40%;
HR, .55; P ¼ .06), relapse-related mortality (37% versus 28%; HR, .53; P ¼ .09), and a lower progression-free
survival (36% versus 53%; HR, .56; P ¼ .05). Median donor T cell chimerism levels were signiﬁcantly lower
in the TBI group at days 28 (61% versus 90%; P < .0001) and 84 (68% versus 92%; P < .0001), as was NK cell
chimerism on day 28 (75% versus 96%; P ¼ .0005). In conclusion, this randomized trial demonstrates the
importance of ﬂudarabine in augmenting the graft-versus-tumor effect by ensuring prompt and durable high-
level donor engraftment early after transplantation.
 2013 American Society for Blood and Marrow Transplantation.During the development of the widely used non-
myeloablative conditioning regimen based on 2-Gy low-dose
total body irradiation (TBI) and 90 mg/m2 ﬂudarabine (FLU),
the ﬁrst 44 patients in the initial clinical trial were condi-
tioned with a regimen directly translated from our canine
studies [1-3]. The regimen consisted of 2-Gy TBI alone, and
although results were encouraging, a nonfatal graft rejection
rate of 20% was observed [4]. To reduce the high rejection
rate, FLU (30 mg/m2/day for 3 days) was added to the 2-Gy
TBI, which resulted in a decrease in rejections to 3% [5].
However, in a retrospective analysis of the ﬁrst 176 patientsedgments on page 1346.
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13.06.002with hematologic malignancies treated with non-
myeloablative hematopoietic cell transplantation (HCT) from
HLA-identical related donors, higher nonrelapse mortality
(NRM) was observed among patients conditioned with 2-Gy
TBI and FLU (FLU/TBI) (FLU/TBI: 31% versus TBI:14% at 2 years;
P ¼ .02). The increased NRM was due to increased infectious
events with or without graft-versus-host disease (GVHD) [5].
As rejections were mainly observed in patients who had
not been treated with signiﬁcant myelosuppressive chemo-
therapy [5] (myeloid malignancies or multiple myeloma)
before allogeneic HCT, we hypothesized that in patients at
a low risk of rejection, conditioning with 2-Gy TBI alone
could be sufﬁcient to allow stable long-term engraftment.
These results needed to be taken with caution, however, as
they were retrospective and not from concurrent trans-
plantation cohorts. Therefore, we initiated this phase III trial,Transplantation.
B. Kornblit et al. / Biol Blood Marrow Transplant 19 (2013) 1340e1347 1341where patients at low or moderate risk of rejection were
randomized between conditioning with 2-Gy TBI alone or in
combination with FLU (30 mg/m2/day for 3 days)/FLU/TBI)
before transplantation with peripheral blood stem cells
(PBSC) from human leukocyte antigen (HLA)-matched
related donors.
PATIENTS AND METHODS
The study was a randomized phase III trial including 9 transplantation
centers: Fred Hutchinson Cancer Research Center (FHCRC), Medical College
of Wisconsin, University of Leipzig, Oregon Health and Science University,
VA Puget Sound Health Care System Huntsman Cancer Institute/University
of Utah, University of Torino School of Medicine, LDS Hospital, University of
Tuebingen, and University of Cologne. The FHCRC acted as the coordinating
center. The study was approved by the institutional review board at each
center, and written informed consent was obtained from all patients before
the start of treatment.
Randomization, Study Endpoints, and Accrual
Patients were randomized equally between conditioning with 2-Gy TBI
alone or in combination with FLU 30 mg/m2/day for 3 days. The randomi-
zationwas performed at the FHCRC andwas stratiﬁed balanced over time for
institution, disease risk (indolent versus aggressive) [6], and a history of
prior high-dose HCT.
The initial primary endpoint was the comparison of 1-year NRM
between arms. However, as accrual was slow, and it was unlikely that the
enrollment goal of 200 patients would be met within a reasonable time-
frame, the data safety monitoring board recommended a change of the
primary objective to overall survival at 3 years to accommodate a lower
accrual goal of 110 patients. Apart from including NRM at 1 year in the
secondary objectives, the rest of the secondary objectives remained the
same (disease progression, relapse-related mortality, graft rejection, grades
II to IV acute and chronic GVHD, infections, and immune reconstitution).
The protocol was opened for accrual in December 2003 and closed by
the principal investigator (with data safety-monitoring board approval) in
May 2011, after accruing 85 patients, because of a difference in relapse and
progression rates between the 2 arms.
The database was analyzed as of December 12, 2012.
Eligibility Criteria
Included in this study were patients with hematological malignancies
treatable by allogeneic HCTwhowere not curable by high-dose conditioning
with autologous stem cell support and ineligible for high-dose allogeneic
HCT because of age or comorbidities. Donors were related and at least
genotypically HLA identical at 1 haplotype and phenotypically or genotyp-
ically identical at the allele level at HLA-A, -B, -C, -DRB1 and -DQB1 for the
second haplotype [7]. The hematological malignancies allowed were
aggressive non-Hodgkin lymphomas (NHLs); low-grade NHL with
<6 months’ duration of complete remission (CR) between courses of
therapy; mantle cell lymphoma; chronic lymphocytic leukemia (CLL) that
did not meet the National Cancer Institute’s Working Group criteria for CR,
partial remission, or relapse within 12 months after FLU or other nucleoside
analogue-containing therapy; failed FLU-cyclophosphamide-rituximab
therapy, had 17p deletion; progressed to prolymphocytic leukemia or
T cell CLL or prolymphocytic leukemia; Hodgkin lymphoma (HL) that had at
least failed frontline therapy and were ineligible for or had failed high-dose
conditioning with autologous stem cell support; multiple myeloma (MM)
that was chemotherapy sensitive after failed high-dose conditioning with
autologous stem cell support; acute myeloid leukemia (AML) or acute
lymphoblastic leukemia beyond ﬁrst CR; chronic myeloid leukemia (CML)
beyond the ﬁrst chronic phase after myelosuppressive therapy; myelodys-
plastic syndrome (MDS) or myeloproliferative disease after myelosup-
pressive therapy; or Waldenstrom’s macroglobulinemia after failing 2
courses of therapy. Patients with CML, AML, acute lymphoblastic leukemia,
MDS, or myeloproliferative disease required < 5% marrow blasts at the time
of transplantation. Myelosuppressive therapy less than 3 weeks before
conditioning or high-dose conditioning with stem cell support less than
6 months before allogeneic HCT was not allowed.
Patients were excluded from the trial if they were pregnant or breast-
feeding; had rapidly progressing intermediate- or high-grade NHL, unless
in minimal disease state; chronic myelomonocytic leukemia, leukemic
blasts in the peripheral blood detected by standard pathology; central
nervous system involvement refractory to intrathecal chemotherapy;
infection with human immunodeﬁciency virus, bacterial, viral, or fungal
infections unresponsive to therapy; decompensated liver disease; lung
carbon monoxide diffusion capacity <30%, total lung capacity <30%, forced
expiratory volume <30%, or dependency on supplementary oxygen;symptomatic coronary artery disease or cardiac ejection fraction <35%;
poorly controlled hypertension; or a Karnofsky performance score <50%.
Treatment and Evaluations
Patients allocated to the TBI-onlyarmreceived2Gyat a rate of .07Gy/min
to .10 Gy/min from a linear accelerator on the day of HCT (day 0) with PBSC,
whereaspatients in the FLU/TBI arm in addition receivedFLU (30mg/m2/day)
on days -4, -3, and -2 before 2-Gy TBI and HCT. PBSC were collected from
related donors ondays -1 and 0 (CD34þ target cell dosewas 5106 cells/kg of
recipient weight) after administration of granulocyte colony-stimulating
factor (G-CSF) (16 mg/kg) on days -4 to 0. Postgrafting immunosuppression
consisted of oral cyclosporine (CSP; 5mg/kg twice daily from days -3 toþ56,
and, in the absence of GVHD, tapered by 6% weekly until day þ180) and
mycophenolate mofetil (15 mg/kg twice daily from day 0 toþ27). CSP levels
were monitored by immunoassay, and whole blood trough levels were tar-
getedat500ng/mL for theﬁrst 28days after transplantationandat150ng/mL
to450ng/mLuntil the start of taper (Abbott, TDX, Abbott Park, IL). If therewas
evidence of persistent/progressive disease or relapse in the absence of GVHD
on day 56 after transplantation, all immunosuppressive agents were rapidly
tapered to allowgraft-versus-tumor effects to occur. If relapsewas observed,
these cases were considered treatment failures, and the patients were taken
off protocol. Donor lymphocyte infusion (DLI) was not offered on this
protocol, and patients with low chimerism or disease progression were
eligible for ongoing DLI protocols or treatment plans. For the purpose of
survival analysis, patientswere followed past the time point of relapse or DLI.
Chimerism analysis was performed as previously described [8]. Peripheral
blood CD3þ T cell chimerism studies were performed on days þ28, þ84
and þ365, and, if the patient had <50% donor chimerism on day 28, addi-
tional analyseswere performed on daysþ56 andþ180. If the patient was not
>95%CD3þTcell donor chimerismat1year, analyseswere repeatedannually.
Natural killer (NK) cell (CD56) and granulocyte (CD33) chimerisms were
obtained on days þ28 and þ84, respectively. Full-donor chimerism was
deﬁned as >95% donor CD3þ T cells, and graft rejection was deﬁned as the
inability todetect at least 5% donor CD3þ Tcells inperipheral blood. Toxicities
were determined using the Common Toxicity Criteria, Version 2.0 [9].
All patients received standard prophylaxis against infections as previ-
ously published [10]. Diagnosis, clinical grading, and treatment of acute and
chronic GVHD were performed by local investigators according to estab-
lished criteria [11,12]. Tumor responses were assessed using standard
criteria and PCR, cytogenetics, ﬂuorescein in situ hybridization, and ﬂow
cytometric-based methods as appropriate.
Analysis of Peripheral Blood Lymphocytes
Immunnophenotyping of peripheral blood lymphocytes was only per-
formed in a subset of patient/donor pairs that underwent transplantation at
the FHCRC. Peripheral blood was obtained from donors pre-G-CSF and from
patients before transplantation and at days þ28, þ84, þ180 and þ365.
Enumeration of mononuclear cell subsets [13] and immunophenotyping by
ﬂow cytometry for naïve and memory B cells, naïve and memory/effector
CD4þ and CD8þ T cells, monocytes, NK cells, and myeloid and plasmacytoid
dendritic cells were performed as previously described [13,14].
Statistical Analysis
Survival was estimated by the Kaplan-Meier method. Cumulative
incidence was estimated by standardmethods in the competing risk setting.
Nonrelapse death was a competing risk for the analysis of relapse/
progression and relapse-related mortality, and, conversely, relapse/
progressionwas a competing risk for the analysis of nonrelapse death. Death
was a competing risk for the analysis of acute and chronic GVHD and
infection. All statistical comparisons of time-to-event endpoints are based
on hazard ratio (HR) analysis using Cox regression. Comparisons of chime-
rism are based on 2-sample Wilcoxon test. Comparisons of immune
reconstitution are based on 2-sample t-test. All P values are 2 sided.
RESULTS
Patients
Forty-four patients were accrued into the TBI-only arm,
and 41 were accrued into the FLU/TBI arm. Patient demo-
graphics are summarized in Table 1. Overall median patient
age was 55 (range, 17 to 73) years with a predominance of
male gender (68%). Patients received G-CSFemobilized PBSC
containing a median of 7.9  106 (range, 1.9  106 to
22.7  106) CD34þ cells/kg and 3.6  108 (range, 1.0  108 to
40.9  108) CD3þ cells/kg. Underlying diseases were AML
(n ¼ 15), MDS (n ¼ 4), NHL (n ¼ 32), CLL (n ¼ 9), MM (n ¼ 9),
Figure 1. Donor granulocyte and T cell chimerism. Percent donor granulocyte
(A) and T cell chimerism (B) in patients conditioned with 2-Gy total body
irradiation only (TBI, n ¼ 44) or in combination with 90 mg/m2 ﬂudarabine
(FLU/TBI, n ¼ 41). Horizontal lines represent medians, and dots represent the
individual data points. P values are 2 tailed.
Table 1
Pretransplantation Demographics
Characteristic TBI Only
(n ¼ 44)
Flu/TBI
(n ¼ 41)
Patient age, median (range), yr 54 (17-73) 56 (18-72)
Male patient gender 32 (73) 26 (63)
Donor age, median (range), yr 53 (17-73) 54 (15-71)
Sex of patient/donor
Male/female 15 (34) 15 (37)
Other combinations 29 (66) 26 (63)
CMV serostatus of patient/donor
Negative/negative 14 (32) 12 (29)
Other combinations 30 (68) 29 (71)
Prior failed high-dose HCT
Autologous 23 (52) 21 (51)
Allogeneic 3 (7) 0
Number of previous regimens,
median (range)
5 (1-17) 5 (1-19)
Diagnoses
Non-Hodgkin lymphoma 14 (32) 18 (44)
Acute myeloid leukemia 10 (23) 5 (12)
Multiple myeloma 5 (11) 4 (10)
Chronic lymphocytic leukemia 5 (11) 4 (10)
Myelodysplastic syndrome 2 (5) 2 (5)
Hodgkin lymphoma 8 (18) 8 (20)
Relapse risk [15]
Low 9 (20) 14 (34)
Standard 18 (41) 12 (29)
High 17 (39) 15 (37)
HCT comorbidity index
0 13 (30) 6 (15)
1,2 6 (14) 13 (33)
3þ 24 (56) 20 (51)
CD34þ cells  106/kg, median (range) 7.9 (2.6-19.8) 7.7 (1.9-22.7)
CD3 þ cells  108/kg, median (range) 3.7 (1.4-40.9) 3.5 (1.0-9.7)
Data presented as n (%) unless otherwise indicated.
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compared with AML and lower relapse risk score [15] in the
FLU/TBI arm, but this was not statistically different and
within the limits expected by chance. Fifty-ﬁve percent
of the patients had failed at least 1 high-dose HCT.
As randomization was stratiﬁed upon failed prior high-
dose HCT, the number of patients was evenly distributed
between arms (TBI only, n¼ 26 [59%]; FLU/TBI, n¼ 21 [51%]).
In the TBI arm, 3 of 26 patients had failed an allogeneic
HCT (all from different HLA-matched siblings) compared
with none in the FLU/TBI arm. There was no difference in
median HCT comorbidity index between arms [16]. Four
patients in the TBI arm and 3 in the FLU/TBI arm, all with
refractory or relapsed CD20þ B cell lymphomas, were
concurrently enrolled on a protocol (ClinicalTrials.gov iden-
tiﬁer: NCT00867529) studying the effects of peri-
transplantation rituximab (days -3, 10, 24 and 38).
Peripheral Blood Cell Changes, Rejections, and Chimerism
All patients had initial engraftment. Although no patients
in the FLU/TBI arm rejected their grafts, 2 patients in the TBI
arm, 1 with AML in second CR and 1 with MDS (refractory
anemia with excess of blasts-2), experienced graft rejection
31 and 262 days after transplantation, respectively. The
patient with AML had failed a prior allogeneic high-dose HCT
from a different HLA-matched sibling, and after rejecting the
graft from the current 2-Gy TBI-conditioned HCT, went on to
receive a third allogeneic HCT from the same sibling and
subsequently died from disease progression. The patient
with MDS was in complete remission before transplantation,
having received only 1 cycle of cytarabine and mitoxantrone.
After rejecting the graft on this trial, the patient received
a second myeloablative transplantation from a syngeneicdonor. The patient was still alive and in remission at last
follow-up.
Near-complete donor granulocyte chimerism was ach-
ieved promptly, with no signiﬁcant differences between arms
(Figure 1A). Median donor T cell chimerism levels were
signiﬁcantly higher in the FLU/TBI arm comparedwith the TBI
arm at days þ28 (90% versus 61%; P < .0001) and þ84 (92%
versus 68%; P < .0001) (Figure 1B). Median day þ28 NK cell
donor chimerism was also signiﬁcantly higher in FLU/TBI-
conditioned patients (FLU/TBI [n¼ 14], 96%; TBI [n¼ 15], 75%;
P ¼ .0005) and correlated with day þ28 donor T cell chime-
rism (Pearson’s correlation coefﬁcient ¼ .82; P < .0001).
Median absolute granulocyte count nadirs were similar
in the 2 groups (TBI: 396 [range, 0 to 2340] cells/mL; FLU/TBI:
270 [0 to 1090] cells/mL; P ¼ .32). However, the median
number of days with absolute granulocyte counts below
500 cells/mL was signiﬁcantly higher in the FLU/TBI group
(TBI: 0 [range, 0 to 40] days; FLU/TBI: 4 [range, 0 to 17] days;
P ¼ .05), but the number of patients who required G-CSF
treatment for prolonged neutropenia (persistence or devel-
opment of granulocyte counts below 500 cell/mL past
day þ21 after transplantation) was similar (TBI: 12%; FLU/
TBI: 18%; P¼ .45). Platelet nadirs (TBI: 59,000 [range, 6000 to
251,000] platelets/mL; FLU/TBI: 59,000 [range, 6000 to
209,000] platelets/mL; P ¼ .62) and days below platelet
counts of 20,000 platelets/mL (TBI: 0 [range, 0 to 24] days;
FLU/TBI: 0 [range, 0 to 3] days; P ¼ .63) were similar in both
Figure 2. Immune reconstitution. Mean absolute numbers of natural killer (NK) cells (A), CD4þ (B), naïve CD4þ (C), and memory/effector CD4þ (D) cells at days 28
(TBI: n ¼ 16; FLU/TBI: n ¼ 7) and 90 (TBI: n ¼ 8; FLU/TBI: n ¼ 13) after transplantation in patients conditioned with 2-Gy total body irradiation only (TBI) or in
combination with 90 mg/m2 ﬂudarabine (FLU/TBI). Bars represent standard error of the mean. P values are 2 tailed.
B. Kornblit et al. / Biol Blood Marrow Transplant 19 (2013) 1340e1347 1343arms. The percentages of patients who needed red blood cell
transfusions trended to be higher in the FLU/TBI arm (TBI:
43%; FLU/TBI: 63%; P ¼ .06), whereas the percentages of
patients who needed platelet transfusions were similar in
both arms (TBI: 23%; FLU/TBI: 27%; P ¼ .66).DLI
None of the patients in the FLU/TBI arm received DLI.
A total of 8 patients in the TBI arm received DLI: 2 patients
because of low chimerism (both died from relapsed AML)
and 6 patients because of relapse or progression (4 died from
relapse, whereas 1 with HL and 1 with small lymphocytic
lymphoma were alive at last follow-up).Immune Reconstitution
In the TBI arm, samples for immunophenotyping were
available from 16 patients at day 28 and from 8 patients at
day 90, whereas in the FLU/TBI arm, samples were available
from 7 and 13 patients at days 28 and 90, respectively.Figure 3. Graft-versus-host disease. Cumulative incidences of grade II to IV acute (
irradiation only (TBI) or in combination with 90 mg/m2 ﬂudarabine (FLU/TBI).Immunophenotyping showed that the median absolute
number of NK cells was signiﬁcantly higher at day þ28 after
transplantation in the FLU/TBI arm compared with the TBI
arm (Figure 2). The difference disappeared by day þ90. No
differences between arms were observed for the median
absolute number of CD4þ cells at day þ28, but at day þ90,
lower levels were observed in patients in the FLU/TBI arm
compared with the TBI arm (signiﬁcant for naïve CD4þ cells
and a trend for the CD4 memory/effector population
[Figure 2]). There were no signiﬁcant differences between
arms in absolute counts of naïve and memory/effector CD8þ
T cells, naïve and memory B cells, monocytes, and myeloid
and plasmacytoid dendritic cells at any posttransplantation
time point and in the counts of NK cells and naïve and
memory/effector CD4 T cells on day 180 and 365 (data not
shown).GVHD
The cumulative incidences of grades II to IV and grades III
to IV acute GVHD at 120 days in the TBI arm were 32% andA) and chronic (B) GVHD among patients conditioned with 2-Gy total body
B. Kornblit et al. / Biol Blood Marrow Transplant 19 (2013) 1340e1347134411%, respectively, and in the FLU/TBI arm, 46% (grades I to IV
acute GVHD: HR, 1.60 [95% conﬁdence interval (CI), .8 to 3.1];
P¼ .16) and 7% (grades III to IV acute GVHD: HR, .66 [95% CI, .2
to 2.7]; P ¼ .56), respectively (Figure 3A). Although the
cumulative incidence of chronic GVHD was higher in the
FLU/TBI arm at 3 years (72% versus 48%), the difference did
not reach statistical signiﬁcance (HR, 1.52 [.9 to 2.7]; P ¼ .14)
(Figure 3B).
Regimen-Related Toxicities, Infections, and NRM
The most common toxicities were, as expected, reversible
neutropenia and thrombocytopenia. In general, toxicities
unrelated to the blood and bone marrow were mild with 14
patients in both arms (TBI arm: 32%, FLU/TBI arm: 34%)
experiencing 1 or more grade III to IV toxicities. No differ-
ences in distribution of toxicities were observed between
arms (Supplementary Table 1). One patient in the FLU/TBI
arm developed a squamous cell carcinoma 3.5 years after
transplantation. The cumulative 3-year incidences of bacte-
rial (TBI: 64%, FLU/TBI: 68%; P ¼ .52), viral (TBI: 60%, FLU/TBI:
68%; P ¼ .27), and fungal (TBI: 21%, FLU/TBI 22%; P ¼ .87)
infections were similar in the 2 arms. NRM at 3 years was 9%
in the TBI arm and 7% in the FLU/TBI arm (HR, .67 [95% CI,
.1 to 3.0]; P ¼ .59) (Figure 4). Of the 4 NRM deaths in the TBI
arm, 1 was due to chronic GVHD, and 1 was due to multiple
pulmonary emboli and hemolytic uremic syndrome,
whereas 2 were caused by GVHD complicated with severe
sepsis on days 194 and 287 after transplantation. In the FLU/
TBI arm, 3 NRM deaths were observed on days 9, 59, and 254,
all associated with sepsis.
Relapse and Survival
At the time of analysis, the median follow-up of 48
surviving patients was 5 (range, 1.5 to 8) years. There was
a trend for a higher progression/relapse rate in the TBI arm
than in the FLU/TBI arm (55% versus 40% at 3 years; HR, .55
[95% CI, .3 to 1.0]; P ¼ .06) (Figure 5A), which translated into
a trend toward a higher relapse-related mortality (37%
versus 28% at 3 years; HR, .53 [95% CI, .3 to 1.1]; P ¼ .09)
(Figure 5B) and worse progression-free survival (36% versus
53% at 3 years; HR, .56 [95% CI, .3 to 1.0]; P ¼ .05) (Figure 6A).
Because of limited sample size, it was not possible to evaluate
if the effects of FLU vary according to disease; however,Figure 4. Nonrelapse mortality. Cumulative incidence of nonrelapse mortality
among patients conditioned with 2 Gy total body irradiation only (TBI) or in
combination with 90 mg/m2 ﬂudarabine (FLU/TBI).similar trends of increased relapse in the TBI arm were
observed when patients with lymphoid and myeloid malig-
nancies were analyzed separately (data not shown).
Twenty-six patients relapsed in the TBI arm. At the end of
follow-up, 3 were alive with relapsed disease (HL, n ¼ 2;
NHL, n ¼ 1), whereas 4 (HL, n ¼ 1; NHL, n ¼ 2; MM, n ¼ 1)
were brought back into remission. In the FLU/TBI arm, 16
patients relapsed, of whom 5 were alive at the end of follow-
up. One of the 5 who had HL was brought back into remis-
sion, 3 had progressive disease, and 1 patient with CLL had
stable disease.
Compared with the TBI arm, there was a trend toward
higher overall survival in the FLU/TBI arm (54% versus 65% at
3 years; HR, .57 [95% CI, .3 to 1.1]; P ¼ .09) (Figure 6B).
DISCUSSION
Historically, the addition of FLU to 2-Gy TBI to the
conditioning regimen successfully reduced the rejection
rate from 20% to 3%, by augmenting the pretransplantation
immunosuppression [4,5,17]. In a retrospective analysis of
the ﬁrst 176 patients, however, the question of whether
adding FLU to 2-Gy TBI-exposed patients at low to moderate
risk of rejection to unnecessary toxicity was raised [5]. In the
current study, 85 patients at low tomoderate risk of rejection
were randomized to conditioning with either 2-Gy TBI alone
or in combination with FLU. Baseline characteristics were
balanced between groups, except for a slight imbalance
toward more patients with NHL compared with AML in the
FLU/TBI group. Although the number of prior treatment
regimens and transplantations were similar in both groups,
21 of 41 patients in the FLU/TBI arm had failed autologous
transplantations. In the TBI group, 23 of 44 patients failed
autografts and 3 failed allografts. Only 2 rejections were
observed in the trial, both in the TBI-only group. One had
a prior allograft from a different donor, possibly indicating
that donor cells given in the ﬁrst transplantation were not
adequately myelosuppressed with TBI only. For this reason,
the current practice is to condition patients who have failed
prior allografts with 3-Gy TBI in addition to FLU. The second
patient who rejected the graft had only received 1 cycle of
chemotherapy before transplantation, which possibly was
insufﬁciently myelosuppressive.
All patients had initial engraftment, even the 2 who
experienced rejection. Donor granulocyte chimerism was
prompt, with no difference between arms. However, signiﬁ-
cant differences were observed in the rate of achieving donor
T and NK cell chimerism. Patients conditioned with FLU/TBI
had signiﬁcantly higher levels of donor T cell chimerism at
days 28 and 84 after transplantation. Day-28 NK cell chime-
rism was also higher in the FLU/TBI group. Low levels of
donor T and NK cell chimerism have previously been associ-
ated with graft rejection in settings of nonmyeloablative,
reduced-intensity and in high-dose conditioning. In a cohort
of 38 patients who underwent transplantation after condi-
tioning with FLU/TBI, Keil et al. [18] observed that donor
Tcell chimerism<90% at day 28was associatedwith a higher
rejection rate. Similarly, analyses by Baron et al. have
demonstrated that day-14 donor T and NK cell chimerism
levels <50%, conditioning with 2-Gy TBI with or without FLU
(90 mg/m2) were associated with increased graft rejection
[19,20]. In a recent study of pediatric patients conditioned
with a variety of high-dose and reduced-intensity regimens,
early low donor T and NK cell chimerism levels were also
associated with increased risk of graft rejection, regardless of
conditioning intensity [21].
Figure 5. Relapse or progression incidence and relapse-related mortality. Cumulative incidences of relapse or progression (A) and relapse-related mortality (B)
among patients conditioned with 2-Gy total body irradiation only (TBI) or in combination with 90 mg/m2 ﬂudarabine (FLU/TBI).
B. Kornblit et al. / Biol Blood Marrow Transplant 19 (2013) 1340e1347 1345Although the addition of FLU was associated with an
increased number of days with absolute granulocyte counts
below 500 cells/mL and a trend toward increased red blood
cell transfusion needs, no increases in NRM or bacterial, viral,
or fungal infection rates were observed. However, it is
possible that the 2 early septic deaths in the FLU/TBI arm
could be related to FLU. NRM rates in both arms were lower
than in the previous retrospective analysis [5] that prompted
the current study, probably reﬂecting the recent years’
overall improvement in supportive care, which has lowered
NRM in general and, in particular, also negated the effect of
FLU on NRM. Although 55% of the patients in the current
study had failed a high-dose transplantation before entering
the trial, NRM rates still compared favorably to previously
published data on nonmyeloablative regimens, such as ﬂu-
darabine/busulfan in AML/MDS (NRM 26% at 2 years) [22]
and ﬂudarabine/cyclophosphamide/rituximab in follicular
lymphoma (NRM 15% at 5 years) [23]. A recent registry study
investigating the outcome of low-intensity conditioning
allogeneic transplantation in patients with NHL who had
relapsed after autologous transplantations, reported an NRM
of 44% at 3 years [24].
In this study, the relapse/progression incidence, relapse-
related mortality, and progression-free survival were supe-
rior in the FLU/TBI arm, whereas only nonsigniﬁcant trends
toward higher rates of acute and chronic GVHD were
observed. It is possible that some of the effect on relapse may
be due to the antineoplastic effects of the FLU, although this
is unlikely in this patient population.
The observed differences in outcome between arms in our
study were likely due to differences in donor T and NK cellFigure 6. Progression-free survival and overall survival. Cumulative incidences of pro
with 2-Gy total body irradiation only (TBI) or in combination with 90 mg/m2 ﬂudarachimerism kinetics. Our results are in agreement with
previous observations by both Keil et al. [18] and our own
group [19], where donor T cell chimerism <90% (day 28 after
transplantation) and <75% (day 84 after transplantation)
were associated with a higher risk of relapse and lower
progression-free survival. Although it is agreed that the
graft-versus-tumor effects and GVHD after HLA-identical
HCT are mainly a product of T cell activity [25], the roles of
NK cells are far less explored. Killer cell immunoglobulin-like
receptor genes are inherited independently from HLA, and
will be mismatched in 75% of matched related trans-
plantations [26]. In 2 studies by Baron et al., inwhich patients
were conditioned with FLU/TBI, and NK cell chimerism was
investigated along with T cell chimerism, T cell chimerism
was mainly associated with the development GVHD,
whereas rapid development of NK cell chimerism was asso-
ciated with lower relapse rates and better progression-free
survival [20,27]. Notably, no association between NK cell
chimerism and GVHD was observed [27]. As T and NK cell
chimerism correlated closely at day þ28 in our study, it is an
open questionwhether the superior outcomes in the FLU/TBI
arm were due to faster, more complete donor T cell chime-
rism, NK cell chimerism, or both.
Reconstitution of immune cells was similar between
arms, except for NK and CD4þ T cells. Why only CD4þ T cell
counts were affected in the current study is not clear, but
these results are in line with ﬁndings by De Bock et al. that
showed levels of CD4þ cells, including naïve CD4þ, regen-
erated slower than other cell subsets after nonmyeloablative
conditioning with ﬂudarabine and low-dose TBI [28].
Although our ﬁndings should be interpreted with cautiongression-free survival (A) and overall survival (B) among patients conditioned
bine (FLU/TBI).
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sent an effect induced by ﬂudarabine, as both CD8þ and CD4þ
cells have been shown to be highly sensitive to depletion by
ﬂudarabine in CLL [29], whereas NK cells have been shown to
be more resistant [30], explaining the higher NK and lower
CD4þ cell counts in the FLU/TBI arm. Conversely, with 2-Gy
TBI alone conditioning killing fewer T (including CD4þ) cells,
the higher levels of CD4þ cells could be a consequence of
a longer period with mixed chimerism.
In conclusion, the current study showed that in the
setting of a randomized phase III clinical trial, the addition of
FLU (30 mg/m2) for 3 days to conditioning with 2-Gy TBI
before allogeneic HCT from HLA-matched related donors
with CSP and mycophenolate mofetil as postgrafting GVHD
prophylaxis is safe and efﬁcacious. FLU did not increase NRM
or the incidence of infections and was associated with lower
relapse and better progression-free survival, probably
because of the induction of higher levels of donor T and NK
cell chimerism early after transplantation. Furthermore, the
study suggests that donor engraftment in heavily pretreated
patients is possible with only 2-Gy TBI, but that a lower
conditioning intensity correlates to a slower speed of
engraftment, which may be associated with a decrease in
successful outcome.
Although NRM is low with the current nonmyeloablative
regimens, relapse still represents a challenge. In the context
of reduced-intensity regimens, where conditioning intensity
and antineoplastic activity is increased compared with the
nonmyeloablative regimens, the possible beneﬁcial effects
on relapse rates are counterbalanced by an increase in NRM
at 19% to 25% [31-33].
A possible solution to this problem could be further
studies with minimal conditioning intensity, where the issue
of slow development of donor chimerism could be
approached by augmenting the antitumor effect by adding
disease-speciﬁc agents, such as anti-CD20 antibodies [34] or
receptor tyrosine kinase inhibitors [35], in the post-
transplantation period, thereby allowing full-donor chime-
rism ample time to develop. A different approach could also
include substituting external beam radiation with targeted
a-emittere labeled anti-CD45e based radioimmunotherapy,
which reduces off-target radiation toxicity and increases
radiationdose selectively in cells responsible for rejection and
tumor cells [36].ACKNOWLEDGMENTS
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